ArticleJournal of the American Chemical Society2008
Rational design of protein-based MRI contrast agents.
Article in Journal of the American Chemical Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 138 citations in OpenAlex.
- Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent.Science advances · 2026Article
- Gadolinium Pollution-A Future Forward Perspective on Human and Environmental Impact.Magnetic resonance in medicine · 2026Review
- Single-point mutated lanmodulin as a high-performance MRI contrast agent for vascular and kidney imaging.Nature communications · 2024Article
- Spatial Multiplexing and Omics.Nature reviews. Methods primers · 2024Article
- Early Detection and Staging of Lung Fibrosis Enabled by Collagen-Targeted MRI Protein Contrast Agent.Chemical & biomedical imaging · 2023Article
- Rational design of a genetically encoded NMR zinc sensor.Chemical science · 2023Article
- Metal-Assembled Collagen Peptide Microflorettes as Magnetic Resonance Imaging Agents.Molecules (Basel, Switzerland) · 2023Article
- Novel albumin-binding multifunctional probe for synergistic enhancement of FL/MR dual-modal imaging and photothermal therapy.Frontiers in chemistry · 2023Article
- Large Protein Assemblies for High-Relaxivity Contrast Agents: The Case of Gadolinium-Labeled Asparaginase.Bioconjugate chemistry · 2022Article
- Cutting edge rare earth radiometals: prospects for cancer theranostics.EJNMMI radiopharmacy and chemistry · 2022Review
- Using ELP Repeats as a Scaffold for De Novo Construction of Gadolinium-Binding Domains within Multifunctional Recombinant Proteins for Targeted Delivery of Gadolinium to Tumour Cells.International journal of molecular sciences · 2022Article
- Recent Advances in Gene Therapy for Cancer Theranostics.Current opinion in biomedical engineering · 2021Article
- Capturing an elusive but critical element: Natural protein enables actinium chemistry.Science advances · 2021Article
- Nucleus-Targeted Photosensitizer Nanoparticles for Photothermal and Photodynamic Therapy of Breast Carcinoma.International journal of nanomedicine · 2021Article
- Molecular MR Imaging of Prostate Cancer.Biomedicines · 2020Review
- Molecular Sensing with Host Systems for HyperpolarizedMolecules (Basel, Switzerland) · 2020Review
- Design of Calcium-Binding Proteins to Sense Calcium.Molecules (Basel, Switzerland) · 2020Review
- Early detection and staging of chronic liver diseases with a protein MRI contrast agent.Nature communications · 2019Article
- Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.Chemical reviews · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
We describe the rational design of a novel class of magnetic resonance imaging (MRI) contrast agents with engineered proteins (CAi.CD2, i = 1, 2,..., 9) chelated with gadolinium. The design of protein-based contrast agents involves creating high-coordination Gd(3+) binding sites in a stable host protein using amino acid residues and water molecules as metal coordinating ligands. Designed proteins show strong selectivity for Gd(3+) over physiological metal ions such as Ca(2+), Zn(2+), and Mg(2+). These agents exhibit a 20-fold increase in longitudinal and transverse relaxation rate values over the conventional small-molecule contrast agents, e.g., Gd-DTPA (diethylene triamine pentaacetic acid), used clinically. Furthermore, they exhibit much stronger contrast enhancement and much longer blood retention time than Gd-DTPA in mice. With good biocompatibility and potential functionalities, these protein contrast agents may be used as molecular imaging probes to target disease markers, thereby extending applications of MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.